Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pathogenic markers in essential thrombocythemia.

Rosemary E Gale1

  • 1Department of Haematology, University College London, 98 Chenies Mews, London WC1E 6HX, UK. rosemary.gale@ucl.ac.uk

Current Hematology Reports
|August 7, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.

Blood·2026
Same author

Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients.

Journal of hematology & oncology·2024
Same author

Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.

Nature communications·2022
Same author

Therapy for isocitrate dehydrogenase 2 (IDH2)<sup>R172</sup> -mutant acute myeloid leukaemia.

British journal of haematology·2021
Same author

Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.

Nature communications·2021
Same author

Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemia.

Leukemia research·2021
Same journal

Safety and efficacy of argatroban in patients with heparin-induced thrombocytopenia.

Current hematology reports·2006
Same journal

The treatment of immune thrombocytopenic purpura in children.

Current hematology reports·2006
Same journal

Volume-reduced platelet concentrates.

Current hematology reports·2006
Same journal

Platelet transfusions in infants with necrotizing enterocolitis.

Current hematology reports·2006
Same journal

Methods for counting platelets in severe thrombocytopenia.

Current hematology reports·2006
Same journal

Flow cytometry for the diagnosis of autoimmune thrombocytopenia.

Current hematology reports·2006
See all related articles

Diagnosing essential thrombocythemia (ET) is challenging due to its heterogeneity. New markers like X-chromosome inactivation and PRV-1 expression show promise in distinguishing ET from other conditions and predicting thrombosis risk.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Essential thrombocythemia (ET) diagnosis relies on excluding other disorders.
  • ET is a heterogeneous myeloproliferative neoplasm.
  • Current diagnostic methods lack specific markers for ET.

Purpose of the Study:

  • To identify novel diagnostic and prognostic markers for essential thrombocythemia.
  • To investigate the role of X-chromosome inactivation patterns in ET.
  • To evaluate the utility of c-Mpl staining and PRV-1 expression in differentiating ET.

Main Methods:

  • Analysis of X-chromosome inactivation patterns in ET patients.
  • Bone marrow biopsy examination for c-Mpl staining.
  • Assessment of PRV-1 expression in granulocytes.

Related Experiment Videos

Main Results:

  • Nearly 50% of ET patients exhibit polyclonal myelopoiesis via X-chromosome inactivation, linked to lower thrombosis risk.
  • Reduced and heterogeneous c-Mpl staining may differentiate ET from reactive thrombocytosis.
  • Increased PRV-1 expression aids in distinguishing ET from polycythemia vera.

Conclusions:

  • X-chromosome inactivation patterns, c-Mpl staining, and PRV-1 expression represent potential markers for ET diagnosis and risk stratification.
  • Further prospective studies are required to validate these markers for clinical application.
  • Understanding ET heterogeneity is crucial for improved patient management and therapy.